The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans and is often treated with a CPAP machine, but is often declined due to its cumbersome nature.

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow compounding pharmacies to continue selling unapproved versions of the drugs, according to court documents obtained by Becker's .

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss of about 20%, compared to more than 13% for the rival medicine. Lilly and Novo Nordisk both are leaders in this market today.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

Eli Lilly seeks to defend its interests in a lawsuit challenging the FDA's decision on the supply status of its drugs Zepbound and Mounjaro. The lawsuit, filed by compounding pharmacies, aims to reverse the FDA's determination that these drugs are no longer in short supply.

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that its weight-loss drugs are no longer in short supply.